首页 | 本学科首页   官方微博 | 高级检索  
     

探讨干扰素a-2b联合炎琥宁治疗小儿手足口病的疗效及安全性
引用本文:李兰玲. 探讨干扰素a-2b联合炎琥宁治疗小儿手足口病的疗效及安全性[J]. 现代保健, 2014, 0(32): 61-63
作者姓名:李兰玲
作者单位:山东省临沂市人民医院,山东临沂276000
摘    要:目的:观察并探究干扰素a-2b联合炎琥宁治疗小儿手足口病的临床疗效及安全性。方法:选取本院2012年2月-2013年2月收治的138例小儿手足口病患者为研究对象,随机分为对照组与试验组,每组69例。在给予两组患儿进行对症治疗的基础上,给予对照组利巴韦林进行治疗,试验组患儿则接受干扰素a-2b联合炎琥宁治疗。统计并比较两组患儿的临床疗效及安全性。结果:试验组的总有效率为97.10%,明显高于对照组的84.06%(P〈0.05);试验组的平均治疗时间、用药后患儿的平均退热时间、手足口疱疹的平均消退时间均显著低于对照组,差异具有统计学意义(P〈0.05)。结论:在小儿手足口病的临床治疗过程中,采用干扰素a-2b联合炎琥宁的方法能缩短患儿的手足口疱疹及退热时间,有效防止器官出现感染或衰竭,且不良反应的发生率低,具有较高的安全性,值得推广与应用。

关 键 词:干扰素a-2b  炎琥宁  小儿手足口病  临床疗效  安全性

Efficacy and Safety of Interferon a-2b Combined with Potassium Sodium Dehydroandroan Drographolide Succinate for Pediatric Foot and Mouth Disease
LI Lan-ling. Efficacy and Safety of Interferon a-2b Combined with Potassium Sodium Dehydroandroan Drographolide Succinate for Pediatric Foot and Mouth Disease[J]. , 2014, 0(32): 61-63
Authors:LI Lan-ling
Affiliation:LI Lan-ling(Linyi People's Hospital, Linyi 276000, China)
Abstract:Objective:To discuss the efficacy and safety of the interferon a-2b joint potassium sodium dehydroandroan drographolide succinate used for the pediatric foot and mouth disease.Method:138 cases pediatric foot and mouth disease who were treated at our hospital from February 2012 to February 2013,were randomly divided into comparison group and experimental group, every group had 69 children patients.On the basic of offering the symptomatic treatment to these two group of children patient,the comparison group were gived the ribavirin treatment, the group of experimental group were gived the interferon a-2b joint potassium sodium dehydroandroan drographolide succinate.Statisticed and compared the clinical curative effect and safety of the two group children patients.Result: After a period of drug therapy, the effective rate of experimental group was 97.10%, apparently higher than the comparison group 84.06%, significant difference data;compared with comparison group, the average treatment time of experimental group, average defervescence time of the children patients after using the medicine, hand, foot and mouth sores occurred a significant reduction in the average fading of time,significant difference was found in two groups, data with statistical significance(P〈0.05).Conclusion: In the process of clinical treatment for the pediatric foot and mouth disease, use interferon a-2b joint potassium sodium dehydroandroan drographolide succinate method can shorten the time of the hand, foot and mouth herpes, effective to prevent the occurrence of infection or organ failure, and reduce the incidence of adverse reactions, has the high security, is worthy of popularization and application.
Keywords:Interferon a-2b  Potassium sodium dehydroandroan drographolide succinate  Pediatric foot and mouth disease  Clinical effect  Security
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号